SINGAPORE (Oct 16): Trendlines Medical Singapore, a 76.43%-owned subsidiary of Catalist-listed Israeli company The Trendlines Group, has made its first investment by committing a total of US$60,000 ($81,150) to a medical device start-up, InterVaal.

InterVaal is developing a urological catheter to address catheter associated urinary tract infection.

Trendlines says that its in-house innovation unit, Trendlines Labs, will work with InterVaal’s Singapore-based staff to develop the catheter and conduct clinical trials in Singapore.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook